The teenager who survived cancer, sepsis and a collapsed lung – Wales Online

By Stem Cell Doctors

Teenager Libby Waite first noticed something was wrong with her health on a family holiday to Florida. She felt exhausted the entire time and struggled to walk the shortest of diatances.

And once she returned home and her friends spotted a lump on her neck while admiring her necklace, she knew something more sinister was going on.

After seeing her GP, who sent Libby for blood tests, a private scan and biopsy revealed she had cancer.

She was immediately referred to the Noah's Ark Children's Hospital for Wales in Cardiff where she was diagnosed with the blood cancer Hodgkin lymphoma.

"As a teenage girl, my first concern was about how it would affect my appearance. I was scared I would lose my hair," Libby said.

Her mum Joanne added: "As a mother it's your worst nightmare. I felt like I had my guts wrenched out, it was awful."

Unfortunately, Libby's first few weeks in hospital took a dramatic turn when she contracted sepsis because of her suppressed immune system caused by the first dose of chemotherapy.

"I was so shocked. The doctors had first thought she would have very little side-effects, so no-one expected that reaction," mum Joanne explained.

"One minute she was sat having breakfast, the next she went quiet and unresponsive. It was frightening."

As a result of the sepsis, Libby's lung also collapsed and she had to spend two weeks in intensive care while she recovered.

Libby was eventually able to leave hospital on Christmas Eve 2015.

"Although it had been scary it was so nice to be able to get home for Christmas," said Libby.

Libby, now 18, from Pontypool, returned to hospital where she was able to continue with a different type of chemotherapy.

Despite having four doses, tests revealed that the cancer had not gone away, so she was referred to a specialist consultant in London who recommended immunotherapy - a treatment which uses a persons own modified cells to treat cancer.

It is thought that Libby was one of the first patients in Wales to receive the relatively new treatment back in 2016.

Libby had a stem cell transplant where her own cells were harvested, treated and planted back in to her body to fight the cancer.

This required a three-week isolation period where her immune system was completely supressed.

Unfortunately, Libby did lose her hair as a result of the earlier chemotherapy treatment, but she said: "It actually wasn't as bad as I thought it would be. I had a really cool wig and I was able to use make-up for my eyebrows."

Thankfully the treatment was successful and Libby is now in remission after a long recuperation period at home while she gathered her strength.

She recalled: "I felt so weak, I was confined to the sofa for weeks and I had to rebuild my strength to walk again"

Eventually Libby said she was was able to return to school and sit her GCSEs and go to her year 11 prom.

"Going to prom was the first time I finally felt like a young person again," she admitted.

"I just wanted to go out with my friends and do everything they were doing."

Libby, who is currently applying for university, is now helping Cancer Research UK launch Race for Life at Home in Wales to help carry on the fight against the disease in these unprecedented times.

She took part in her local Race for Life 5k event in Cwmbran in 2017 after her treatment.

The Cwmbran event is among many which the organisers have postponed this spring and summer to protect the countrys health during the coronavirus outbreak.

But as the nation continues on lockdown, undeterred women and men are already vowing to carry on and complete a Race for Life at Home challenge at home, in their garden or their nearest green space.

Many of the scientists and researchers funded by Cancer Research UK are currently being redeployed to help in the fight against Covid-19, including assisting with testing.

By helping to beat coronavirus, the charity said it can lessen the impact it is having on the care of cancer patients.

Video Unavailable

Click to playTap to play

Play now

Cassandra Miles, Cancer Research UKs spokeswoman for Wales, said: "At a time when it feels like everything is at a standstill, there is one thing that hasnt stopped, cancer.

"Our priority as a charity is ensuring that people affected by cancer are getting the support they need right now.

"But we are already getting people asking about doing Race for Life at Home because they dont want to see the charity lose out on vital funding. Its truly humbling to see the response.

"So from their homes, wed love for supporters to join us and Race for Life at Home in these challenging times.

"From a run or 5K walk around the garden to limbo in the living room, there is no wrong way to Race for Life at Home. With no entry fee, people might choose to twerk, limbo, star jump, squat, skip, dance, or come up with their own novel way of taking part and share it with friends. The message is very much that while we might be apart, were doing this together. There is no wrong way to get involved and join our community.

"Those lucky enough to have a garden may choose to make use of it but whatever people decide to do, we are immensely grateful for the support, now more than ever. If the idea takes off, we could be looking at hundreds of people in Wales stepping forward to Race for Life at Home and perhaps collecting sponsorship to do so."

People can visit raceforlife.org and sign up free for ideas on how they can create their own Race for Life at Home challenge.

And the Cancer Research UK Race for Life Facebook page will help people feel energised with weekly live workout sessions.

Organisers are also inviting participants to join the Race for Life at Home community by sharing photos and videos on social media using the hashtag, #RaceForLifeAtHome.

Read the rest here:
The teenager who survived cancer, sepsis and a collapsed lung - Wales Online

Four UTSW Researchers Named to The National Academy of Sciences – D Magazine

By Stem Cell Medical Center

Four UT Southwestern Medical Center scientists have been elected to the The National Academy of Sciences, one of the top honors for American scientists.

Peer scientists selected Sean Morrison, Kim Orth, Michael Rosen, and Sandra Schmid for their original research and achievements. UT Southwestern now has 25 members of the academy, the most of any institution in Texas.

Election to the prestigious National Academy of Sciences recognizes the pioneering contributions these scientists have made to advance our understanding of basic cellular function and molecular processes with application to addressing a broad spectrum of unmet medical needs including cancer and treatments for bacterial infections, said Dr. Daniel K. Podolsky, President of UT Southwestern Medical Center via release. Their election enriches the National Academy of Sciences efforts to provide data and advice on the nations most critical issues in science, health, and medicine.

Morrison is the Director of the Childrens Medical Center Research Institute (CRI) at UT Southwestern and Professor of Pediatrics and has worked in the fields of stem cell biology and cancer, and has created new methods to purify stem cells and allow them to persist and regenerate after injury. This recognizes, first and foremost, the work of many talented people over the years in my lab, most of whom have now gone on to their own laboratories at UT Southwestern and other institutions. Many of the key insights for the important discoveries that were made came from them so this really recognizes their work. Id also like to acknowledge all my colleagues, all of you at UT Southwestern and at Childrens Health, for the incredible environment that you created for science, Morrison said via release.

Orth is a Professor of Molecular Biology and Biochemistry and has discovered biochemical mechanisms behind many bacterial infections, revealing how pathogens use host cells for their own benefit. I want to thank you all for this wonderful celebration, even though we have to Zoom . Thanks to this amazing institution, UT Southwestern, the wonderful administration including Drs. (Daniel) Podolsky and (David) Russell and the other administrators and staff. As (Chair of Molecular Biology) Eric Olson said, I have moved up the ranks here, starting as a technician, to a student, a postdoc, and now Professor, Orth said via release. And this path has driven my success. Another major key to my success is all of the talented people that have worked in my lab and my mentors, friends, collaborators, and, of course, my family.

Rosen is the Chair of Biophysics and Professor in the Cecil H. and Ida Green Comprehensive Center for Molecular, Computational, and Systems Biology, and investigates how cells compartmentalize processes without the use of membranes. When we began our work on phase separation about a decade ago, it really was not obvious at all whether this was going to be some weird, esoteric little thing that a few proteins did or (if) it was going to become a more general principle in biology. So it wasa tremendous risk that many of us took in making a move in this new direction. More than anything, I want to thank the various people whojoined me in taking this great risk a decade ago that I think has proved to be very much worthwhile, Rosen said via release.

Schmid is the Professor and Chair of Cell Biology and is recognized for her work on endocytosis, or how cells absorb nutrients and other molecules, including the major pathway for uptake within the cell. Ive been lucky to start and end my academic career at two unique institutions, Schmid said via release. As a PhD student in the early 80s, I was supported and challenged by my peers and faculty in the Biochemistry department at Stanford to ask important questions and do the most impactful research. Over decades, the leadership at UT Southwestern has inspired, supported and celebrated the very best research creating a collegial culture that breeds success.

This important recognition by their peers reflects the breadth and quality of research underway at UT Southwestern, and serves as inspiration for new generations of trainees and scientists to carry on the tradition of discovery that is the hallmark of distinguished academic medical centers, said Dr. W. P. Andrew Lee., Executive Vice President for Academic Affairs, Provost and Dean of UT Southwestern Medical School via release.

See the article here:
Four UTSW Researchers Named to The National Academy of Sciences - D Magazine

CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma – Yahoo Finance

By Stem Cell Medical Center

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending approval for DARZALEX (daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma in frontline and relapsed/refractory settings. The novel SC formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme's ENHANZE drug delivery technology] and reduces treatment time from hours to approximately three to five minutes, with similar efficacy, and fewer infusion-related reactions compared to intravenous (IV) administration.1,2 The CHMPs Positive Opinion for daratumumab SC formulation applies to all current daratumumab indications including newly diagnosed and transplant-ineligible patients, as well as relapsed or refractory patients.

"Despite therapeutic advances in the treatment of multiple myeloma, the time taken for administration of most intravenous treatments is relatively long and there have been few significant improvements over the years," said Maria-Victoria Mateos, M.D., Ph.D., COLUMBA primary investigator and Director of the Myeloma Unit at University Hospital of Salamanca-IBSAL, Salamanca, Spain. "The daratumumab subcutaneous formulation has the potential to transform the treatment experience for patients and physicians as it reduces time in the chair from hours to minutes, and, because it is administered as a fixed dose from the first treatment, it reduces preparation time and chances of error by eliminating the need for dose calculations."

The Positive Opinion is supported by data from the Phase 3 COLUMBA (MMY3012) and Phase 2 PLEIADES (MMY2040) studies presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and 62nd American Society of Hematology (ASH) Annual Meeting, respectively.1,2 The COLUMBA presentation included a non-inferiority comparison of daratumumab SC formulation to daratumumab IV formulation for co-primary endpoints of overall response rate and maximum Ctrough concentration.1 Furthermore, in a subsequent paper published in The Lancet Haematology, patient-reported treatment satisfaction scores with daratumumab SC versus daratumumab IV were reported using the modified-Cancer Therapy Satisfaction Questionnaire.3 The PLEIADES study evaluated the daratumumab SC formulation in different combination regimens in patients with newly diagnosed multiple myeloma or with relapsed/refractory disease.2

"The subcutaneous formulation of daratumumab showed similar efficacy and fewer infusion-related reactions compared to intravenous daratumumab, and, overall, patients expressed satisfaction with subcutaneous therapy. If approved, we are hopeful this new formulation could offer improved quality of life for patients with multiple myeloma," said Patrick Laroche, M.D., Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. "Janssen is proud to have developed a new formulation to meet the needs of our patients and continue to make a meaningful difference to the lives of those living with multiple myeloma."

"Since its first European approval in 2016, intravenous daratumumab has been used in the treatment of more than 100,000 patients worldwide and, if approved, both new and existing patients with multiple myeloma will be able to start or switch to the subcutaneous formulation as part of their multiple myeloma daratumumab-based treatment regimens," adds Craig Tendler, M.D., Vice President, Clinical Development and Global Medical Affairs, Oncology at Janssen Research & Development, LLC. "Todays Positive Opinion represents Janssens commitment to continuing to improve the treatment experience for patients living with multiple myeloma."

#ENDS#

In Europe, daratumumab is indicated:4

About the COLUMBA Study (MMY3012)3,5The randomised, open-label, multicentre Phase 3 study included 522 patients with multiple myeloma who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both a PI and an IMiD. In the arm that received the subcutaneously (SC) administered formulation of daratumumab (n=263), patients (median age of 65) received a fixed dose of daratumumab 1,800 milligrams (mg) co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) 2,000 Units per millilitre (U/mL), SC weekly for cycles 1 2, every two weeks for cycles 3 6, and every four weeks for cycle 7 and thereafter. In the daratumumab IV arm (n=259), patients (median age of 67) received daratumumab for intravenous infusion 16 milligrams per kilogram (mg/kg) weekly for cycles 1 2, every two weeks for cycles 3 6, and every four weeks for cycle 7 and thereafter. Each cycle was 28 days. Patients in both treatment arms continued until disease progression or unacceptable toxicity. Co-primary endpoints were overall response rate (ORR) (non-inferiority = 60 percent retention of the lower bound [208%] of the 95% CI of the SIRIUS trial, with relative risk [RR] analysed by Farrington-Manning test) and pre-dose cycle 3, day 1 (C3D1) daratumumab Ctrough (non-inferiority = lower bound of 90 percent confidence interval (CI) for the ratio of the geometric means [GM] 80%).

Story continues

About the PLEIADES Study (MMY2040)6 The non-randomised, open-label, parallel assignment study Phase 2 PLEIADES trial included 240 adults either newly diagnosed or with relapsed or refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the subcutaneous formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the subcutaneous formulation plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd cohorts was overall response rate. The primary endpoint for the D-VRd cohort was very good partial response or better rate. An additional cohort of patients with relapsed and refractory multiple myeloma treated with daratumumab plus carfilzomib and dexamethasone was subsequently added to the study.

About daratumumabDaratumumab is a first-in-class7 biologic targeting CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage.8 Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well as through apoptosis, in which a series of molecular steps in a cell lead to its death.4 A subset of myeloid derived suppressor cells (CD38+ MDSCs), CD38+ regulatory T cells (Tregs) and CD38+ B cells (Bregs) were decreased by daratumumab.4 Since launch, it is estimated that 100,000 patients have been treated with daratumumab worldwide.9 Daratumumab is being evaluated in a comprehensive clinical development programme across a range of treatment settings in multiple myeloma, such as in frontline and relapsed settings.10,11,12,13,14,15,16,17 Additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant haematologic diseases in which CD38 is expressed, such as smouldering myeloma.18,19 For more information, please see https://www.clinicaltrials.gov/.

For further information on daratumumab, please see the Summary of Product Characteristics at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex.

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive licence to develop, manufacture and commercialise daratumumab.20

About Multiple MyelomaMultiple myeloma (MM) is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive proliferation of plasma cells.21 In Europe, more than 48,200 people were diagnosed with MM in 2018, and more than 30,800 patients died.22 Almost 60 percent of patients with MM do not survive more than five years after diagnosis.23

Although treatment may result in remission, unfortunately, patients will most likely relapse as there is currently no cure.24 Refractory MM is when a patients disease progresses within 60 days of their last therapy.25,26 Relapsed cancer is when the disease has returned after a period of initial, partial or complete remission.27 While some patients with MM have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.28 Patients who relapse after treatment with standard therapies, including proteasome inhibitors and immunomodulatory agents, have poor prognoses and few treatment options available.29

About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, were creating a future where disease is a thing of the past. Were the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at http://www.janssen.com/emea. Follow us at http://www.twitter.com/janssenEMEA for our latest news. Janssen-Cilag, Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the benefits of daratumumab for the treatment of patients with multiple myeloma. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the companys most recently filed Quarterly Report on Form 10-Q, and the companys subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

ENHANZE is a registered trademark of Halozyme.

# # #

References

1 Mateos MV, Nahi H, Legiec W, et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. J Clin Oncol. 2019;37(Suppl.): abstract 8005.2 Chari A, San-Miguel J, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy: Pleiades study update. Blood. 2019;134(Suppl.1):abstract 3152.3 Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 Mar 23 [epub ahead of print].4 European Medicines Agency. DARZALEX summary of product characteristics. Available at:https://www.ema.europa.eu/documents/product-information/darzalex-epar-productinformation_en.pdf Last accessed April 2020.5 ClinicalTrials.gov. A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma. NCT03277105. Available at: https://clinicaltrials.gov/ct2/show/NCT03277105 Last accessed April 2020.6 ClinicalTrials.gov. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. NCT03412565. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565 Last accessed April 2020.7 Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9:51.8 Fedele G, di Girolamo M, Recine U, et al. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNgamma cytokines and proliferation. Mediat Inflamm. 2013;2013:564687.9 [Data on file]. DARZALEX: New Patient Starts Launch to Date. RF-8220310 ClinicalTrials.gov. A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia). NCT02541383. Available at: https://clinicaltrials.gov/ct2/show/NCT02541383 Last accessed April 202011 ClinicalTrials.gov. A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. NCT02076009. Available at: https://clinicaltrials.gov/ct2/show/NCT02076009 Last accessed April 2020.12 ClinicalTrials.gov. Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. NCT02136134. Available at: https://clinicaltrials.gov/ct2/show/NCT02136134 Last accessed April 2020.13 ClinicalTrials.gov. A study of combination of daratumumab and Velcade (bortezomib) melphalan-prednisone (DVMP) compared to Velcade melphalan-prednisone (VMP) in participants with previously untreated multiple myeloma. NCT02195479. Available at: https://clinicaltrials.gov/ct2/show/NCT02195479 Last accessed April 2020.14 ClinicalTrials.gov. Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in participants with previously untreated multiple myeloma. NCT02252172. Available at: https://clinicaltrials.gov/ct2/show/NCT02252172 Last accessed April 2020.15 ClinicalTrials.gov. A study of Velcade (bortezomib) melphalan-prednisone (VMP) compared to daratumumab in combination with VMP (D-VMP), in participants with previously untreated multiple myeloma who are ineligible for high-dose therapy (Asia Pacific region). NCT03217812. Available at: https://clinicaltrials.gov/ct2/show/NCT03217812 Last accessed April 2020.16 ClinicalTrials.gov. Comparison of pomalidomide and dexamethasone with or without daratumumab in subjects with relapsed or refractory multiple myeloma previously treated with lenalidomide and a proteasome inhibitor daratumumab/pomalidomide/dexamethasone vs pomalidomide/dexamethasone (EMN14). NCT03180736. Available at: https://clinicaltrials.gov/ct2/show/NCT03180736 Last accessed April 2020.17 ClinicalTrials.gov. Study of carfilzomib, daratumumab and dexamethasone for patients with relapsed and/or refractory multiple myeloma (CANDOR). NCT03158688. Available at: https://clinicaltrials.gov/ct2/show/NCT03158688 Last accessed April 2020.18 ClinicalTrials.gov. A study to evaluate 3 dose schedules of daratumumab in participants with smoldering multiple myeloma. NCT02316106. Available at: https://clinicaltrials.gov/ct2/show/NCT02316106 Last accessed April 2020.19 ClinicalTrials.gov. An efficacy and safety proof of concept study of daratumumab in relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. NCT02413489. Available at: https://clinicaltrials.gov/ct2/show/NCT02413489 Last accessed April 2020.20 Johnson & Johnson. Janssen Biotech announces global license and development agreement for investigational anti-cancer agent daratumumab. Press release August 30, 2012. Available at: https://www.jnj.com/media-center/press-releases/janssen-biotech-announces-global-license-and-development-agreement-for-investigational-anti-cancer-agent-daratumumab Last accessed April 2020.21 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction Last accessed April 2020.22 GLOBOCAN 2018. Cancer Today Population Factsheets: Europe Region. Available at: https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf Last accessed April 2020.23 De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254-68.24 Abdi J, Chen G, Chang H, et al. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186207.25 National Cancer Institute. NCI dictionary of cancer terms: refractory. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=350245 Last accessed April 2020.26 Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007:317-23.27 National Cancer Institute. NCI dictionary of cancer terms: relapsed. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45866 Last accessed April 2020.28 American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf Last accessed April 2020.29 Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149-57.

April 2020CP-152796

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005934/en/

Contacts

Media Enquiries: Noah ReymondMobile: +31 621 38 5718Email: NReymond@ITS.JNJ.com

Investor Relations: Christopher DelOreficePhone: +1 732-524-2955

Jennifer McIntyrePhone: +1 732 524 3922

More here:
CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Yahoo Finance

Verify the URL – InnovationMap

By Stem Cell Medical Center

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Fars el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines like a potential coronavirus vaccine more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.

Read more:
Verify the URL - InnovationMap

Houston banking exec shares tips for keeping online information secure amid COVID-19 threats – InnovationMap

By Stem Cell Medical Center

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Fars el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines like a potential coronavirus vaccine more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.

Read the original:
Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap

San Diego biotech firm seeks approval for stem cell research against COVID-19 – CBS News 8

By Stell Cell Research

Personalized Stem Cells Incorporated (PSC) in Poway said the therapy could reduce the most serious complications of the infection in the lungs.

SAN DIEGO A San Diego biotech company is seeking emergency FDA approval for an experimental trial of stem cell therapy for coronavirus patients.

Personalized Stem Cells Incorporated (PSC) in Poway said the therapy could reduce the most serious complications of the infection in the lungs.

PSC CEO, Dr. Bob Harman, said the company is asking to test the treatment on a group of 20 hospitalized COVID-19 patients in the first phase of a clinical trial.

"Stem cell doses will be ready for clinical trial use in May, depending on FDA approval," Harman said.

Harman said they've already scaled up production of stem cells in anticipation of FDA approval.

PSC Medical Director, Dr. Christopher Rogers, stated, "I believe this is the most promising therapy being explored by medical scientists at this time and stem cells may potentially reduce the most serious complications of coronavirus infection."

The FDA has a new program called the Coronavirus Therapeutic Accelerator Program (CTAP) to help speed up the launch of FDA clinical trials for hopeful COVID-19 therapies.

PSC was asked by the White House Coronavirus Task Force to apply to the FDA CTAP program for expedited review of their application.

PSC hopes to rapidly complete the CoronaStem 1 study and then proceed into a larger Phase 2 clinical trial and potentially into FDA compassionate use programs to reach more patients.

More information can be found on the PSC website.

Continue reading here:
San Diego biotech firm seeks approval for stem cell research against COVID-19 - CBS News 8

Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain – BioSpace

By Stell Cell Research

Transparency Market Research (TMR)has published a new report on theamniotic membrane marketfor the forecast period of2019-2027. According to the report, the global amniotic membrane market was valued at ~US$ 980 Mnin2018and is projected to expand at a CAGR of ~10%from2019to2027.

GlobalAmniotic Membrane Market:Overview

Request for Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42059

Increase in Research on Stem Cell Biology & Regenerative Medicineto Drive Market

Cryopreserved Amniotic Membrane Products to Dominate Market

Request for Analysis of the COVID19 Impact on Amniotic Membrane Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42059

Ophthalmology to be Promising Application

Hospitals Account for Major Share of Global Market

North America to Dominate Global Amniotic Membrane Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42059

Global Amniotic Membrane Market: Competitive Landscape

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email:sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com

Go here to read the rest:
Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain - BioSpace

MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development – BioSpace

By Stell Cell Research

MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria). PMU will bring their experience to further the companys global development goals.

Those in attendance from PMU were Herbert Resch, Professor and Rector; Michael Nake, Chancellor; Eva Rohde, Professor, Vice Rector and Director of GMP laboratory; and Mario Gimona, Associate Professor and Head of Production GMP. Those in attendance from MDimune were Shin Gyu Bae, Chief Executive Officer; Seung Wook Oh, Chief Scientific Officer; Tae Kee Jeong, Chief Financial Officer; and Hui-Chong Lau, Manager of the CMC team.

The agreement states that PMU will develop a process for producing CDV therapeutics at GMP-compliant scale as well as supply them for the pre-clinical study and the initial phase of human clinical study. PMU has also agreed to establish GMP-grade mesenchymal stem cell banks derived from umbilical cords for MDimune, which will then be used to produce CDVs required for various preclinical and clinical development.

EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications. However, the fact that they only naturally occur in minuscule quantities and the difficulties involved in large-scale production have prevented a rapid progress in the commercialization of EVs. MDimune developed BioDrone platform technology to overcome these critical limitations in EV therapeutics. MDimune anticipates that the research collaboration with PMU will accelerate the development of CDVs in therapeutics and the initiation of clinical trials in the US, Europe, and Asia, which will lead to more partnerships in the global market.

MDimune also announced the appointment of Dr. Mario Gimona, a leading exosome expert, as Chief Manufacturing Officer. Dr. Gimona has been heading the stem cell and extracellular vesicle (EV) production unit at PMUs GMP laboratory as well as investigating the clinical potential of multipotent mesenchymal stem cell-derived EVs in the field of regenerative medicine. With his expertise in manufacturing of EV therapeutics, he will be able to help advance the clinical applications of BioDrone platform technology.

We are thrilled to announce a joint research endeavor with Paracelsus Medical University. We are confident that this collaboration will expedite the entry into the clinical phase of development for the company, which will allow us to become a global leader in the field of EV therapeutics and ultimately provide a cure for many patients with devastating diseases around the world, said Bae, CEO of MDimune. Dr. Resch, Rector of PMU also emphasized that combining the individual strengths of MDimune and PMU`s GMP unit will enhance therapy development and ultimately change people`s lives.

About MDimune, Inc.

Founded in 2015, MDimune has been dedicated to changing the world by developing innovative therapeutics. The company has developed BioDrone platform technology, which is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone platform technology is patented in the US, Europe, China, Japan, and Korea. MDimunes current programs are focused on cancer, COPD and other rare diseases. MDimune is actively pursuing business partnerships with biotech, pharmaceuticals, and hospitals for the potential application of the BioDrone technology in various unmet medical needs. In 2019, MDimune opened its U.S. affiliate BioDrone Therapeutics Inc. in Seattle, WA, to facilitate its global business development.

For more information, visit the company's website at http://mdimune.com/

Contact

Media:

Jinah Han, Ph.D., Consultant, BD (to.jinah.han@gmail.com)

Investor:

Seung Wook Oh, Ph.D. Chief Scientific Officer (swoh@mdimune.com; info@biodroneus.com)

MDimune Inc.

#1003 KOLON Digital Tower-III, 49 Achasan-ro, Seongdong-gu

Seoul 04790 Korea

Tel +82. 2. 2655. 2636

http://www.mdimune.com

Biodrone Therapeutics Inc.

4000 Mason Rd. Suite 300

Seattle, WA 98195

http://www.biodroneus.com

Original post:
MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development - BioSpace

Covid-19: How scientists are keeping politics out of the global race for a vaccine – FRANCE 24 English

By Stell Cell Research

As the world races to combat the coronavirus, one nation is notably absent from multinational efforts: the United States.But scientists say that for now, the international research community is working together to do all it can.

Global actors are joining forces on multiple fronts to bring the coronavirus pandemic under control. On April 24, the World Health Organization (WHO) held a virtual conference to launch an international collaboration to accelerate the development and production of the health technologies necessary to do so. The United States did not participate in the conference, which culminated in a joint call for action.

Next Monday, May 4, the European Commission will respond to that call by hosting a global virtual conference to raise money from countries and business foundations to fund the development of tests, treatments and a vaccine for the coronavirus. It has invited governments, business leaders, public figures, philanthropists, artists and citizens to help with its efforts to raise the 7.5 billionit has set as its initial target. Announced partners include France, Germany, the United Kingdom, Norway and Saudi Arabia. It remains unclear if the US will take part.

Under President Donald Trumps America First doctrine, the US has tended to favour unilateral action and eschew cooperation with international organisations. Case in point: On March 14, Trump announced that he was suspending funding to the WHO, which has spearheaded the global response to the pandemic. With an annual input of about $400 million, the US is the biggest contributor to the organisation; the reduction in funds comes at a vital moment.

What all that will mean in the battle against a virus that as global health experts have repeatedly reminded us knows no borders and requires coordinated actionremains to be seen.

Politics a separate sphere from science

On the scientific front, the impact may be minimal. While global cooperation and the sharing of expertise and information is critical, it also happens largely without government involvement and, as of now, continues unimpeded, said Laurent Humeau, chief scientific officer at Inovio Pharmaceuticals.

Humeaus team has relied on the sequencing of the genome provided by China, genetic material from Australia and has cooperated with researchers in South Korea and the UK. Its a community that is moving very fast and we need everyone elses help to get a vaccine, he said. Its absolutely critical for us to have this network of scientists.

The Inovio team is part of the WHOs R & D Blueprint, which pulls together a coalition of experts and allows for the rapid activation of research and development activities during epidemics.

And despite the public distance between the US and the WHO, key health personnel from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health continue to be part of the global scientific dialogue. For now, the international research community is working together to do all it can. We keep pushing as fast its not as fast as we can run, but as fast as we can fly, Humeau said.

Unless governments issue restrictions such as those the US imposed on stem-cell research politics tends to exist in a sphere separate from science, said Gregory Poland, director of the Mayo Clinics Vaccine Research Group andwho also edits the international journal Vaccine. Youre not working in a political framework at least in the US youre working in a scientific framework, Poland said.

Researchers end up primarily communicating through journals and meetings and, perhaps most importantly in the current crisis, on "preprint servers", where researchers place articles before they have gone through peer review and been published. That has been the primary way that scientists have been communicating with one another, Poland said.

There may even be a silver lining to a little bit of distance between researchers, said Peter Hotez, dean for the National School of Medicine at the Baylor College of Medicine. The US and Europe sometimes have different approaches to vaccine development and how to support vaccine science, and that may not be so bad because it creates additional opportunities for innovation, he said.

Pushed to the bottom?

Poland hopes that this pandemic, unlike the ones that preceded it, will finally have helped people understand how interrelated their nations are. Weve had multiple examples now, that anything that happens anywhere on this globe is maybe, at most, 36 hours away from Europe or North America, he said. Theres where you need a lot of cooperation, for example, on surveillance, on what is happening where, because literally days are lives.

Finding a vaccine is only a first step, warned David Salisbury, associate fellow in the Global Health Programme at Chatham House. The fact that scientists are talking to each other is admirable, because sharing what we are learning about vaccine development is, of course, hugely important," Salisbury said. But that is the beginning of the story Ultimately, weve got to get from developing a vaccine to manufacturing and buying it country by country, and then were into a political world that has left the scientists behind The critical thing is not when do we get the first dose, its when do we get enough.

Manufacturing and distributing a vaccine will be herculean tasks for a disease that potentially affects everyone on the planet, and thats where a new set of potential problems arises. You could imagine a philosophy of America First that might actually prevent vaccines manufactured in the US from leaving the US until everyone [there] had been vaccinated, Salisbury said. Or what if the EU says we will prioritise European customers first? Geopolitics becomes really important in what becomes available when and for whom.

Salisbury said that countries that cant afford to pay market rate also risk getting pushed to the bottom of this great long list of customers. The international community needs to consider carefully how what are certain to be scarce supplies to begin with get distributed.

How do we share a hugely valuable resource equitably? he asked. I dont know that we have a solution yet.

Read the original post:
Covid-19: How scientists are keeping politics out of the global race for a vaccine - FRANCE 24 English

Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End – Cole of Duty

By Stell Cell Research

In addition to rapid expansion of bone marrow donor registry, increasing commercialization of cellular therapy and tissue engineering, increased survival rate post bone marrow transplant procedures, and easier access to treatment will be some of the most prominent factors driving thebone marrow transplantation market.

According to the latest research by Persistence Market Research, the global bone marrow transplantation market is expected to exceed US$ 12 Bn by the end of 2028. The bone marrow transplantation market is expected to grow at a CAGR of 3.6% through the forecast period 2018-2028.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4288

Company Profile

North America Will Continue to Lead the Pack in Bone Marrow Transplantation Market

Increasing per-capita healthcare and private insurance expenditure is a major factor that is expected to maintain the high demand for technologically advanced treatment procedures, such as bone marrow transplantation, over the forecast period. Increasing blood cancer cases and geriatric population are among the key factors expected to boost the demand for bone marrow transplantation in North America.

The increasing prevalence of myeloma in the region is leading to an increase in the execution of bone marrow transplantation procedures through the allogeneic method. Companies engaged in stem cell therapies are expanding their product portfolio to offer sound treatment solutions for diseases caused while undergoing the allogeneic transplant method.

The availability of more than 90% unrelated donors and high healthcare expenditure are among the factors driving the overall bone marrow transplantation market in North America at present.

The American Society for Blood and Marrow Transplant reported an increasing prevalence of leukemia and lymphoma in patients aged 65 years and above, and this age group constituted 25-30% of the total number of bone marrow transplantation recipients in 2014.

In 2015, the Senate and House of Representatives of the US reauthorized the Stem Cell Therapeutic and Research Act of 2005, which led to an increase in the US unrelated donors registry to 200,000 donors.

Germany Will Steer Europes Market for Bone Marrow Transplantation

Rise in per capita GDP is expected to improve the healthcare expenditure in countries such as Germany and Spain. Government policymakers are forcing healthcare providers and public payers to disclose the cost charged and reimbursed to maintain price transparency. Healthcare organizations in Germany spend most of their research funding on adult stem cell research.

Furthermore, Germany spends 11.3% of its GDP on healthcare, which is above the global average. This, in turn, has led to the presence of better healthcare facilities and more advanced research findings on various healthcare issues such as bone marrow transplantation.

Among the 680 centers throughout the Europe, 226 (35%) centers are dedicated to autologous bone marrow transplantation in 2014, with most of the transplants intended for non-malignant disorders. These factors are expected to drive the bone marrow transplantation market in Europe.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4288

APAC Reflects Lucrative Potential for Penetration of Bone Marrow Transplantation Procedures

Rise in the number of bone marrow transplantation centers and expanding donor registry are among the factors expected to reduce the gap between bone marrow transplantation providers and recipients in the Asia Pacific bone marrow transplantation market.

The availability of modern healthcare amenities, along with the presence of several companies engaged in stem cell therapies in China, Australia, and Japan, is expected to be a key factor driving the overall bone marrow transplantation market in Asia Pacific.

After the introduction of alleviating procedures for Peripheral Blood Stem Cell (PBSC) transplant, there has been an increase in the number of allogeneic HSCT procedures using PBSC (64% of the total HSCT) in Australia & New Zealand, which is another factor contributing to the growth of the bone marrow transplantation market in the region.

A survey by the Eastern Mediterranean Blood and Marrow Transplant (EMBMT) Group suggests that non-malignant indications accounted for a 36.5% share of the total bone marrow transplantation activities carried out in the MEA region. Countries such as Dubai and Qatar are undertaking initiatives to develop national bone marrow registries to enhance bone marrow transplantation rates.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4288

The report offers a comprehensive taxonomy of the bone marrow transplantation market based on the transplantation type, indication, end user, and region.

Continued here:
Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End - Cole of Duty